The landscape for use of cannabidiol (CBD) is rapidly evolving across the United States. Laws regulating the sale, distribution, and possession of CBD are being enacted on a state-by-state basis, creating ambiguity in navigating the medical, legal, and ethical issues surrounding the use of these products. As public opinion propels toward the acceptable use of CBD, patients are increasingly seeking advice and information regarding safe and effective use of these products. Pharmacists are the likely go-to experts to assist the health care team in addressing patient questions and concerns related to CBD and it is imperative that they be well informed on medical literature and legal considerations to effectively navigate these issues within the health system environment.
CBD is a pharmacologically relevant constituent of the cannabis plant, or marijuana, which lacks the intoxicating properties that are attributable to tetrahydrocannabinol (THC), the primary psychoactive constituent of cannabis. CBD products have been widely marketed as human drugs, dietary supplements, additives to food products, e-liquids for vaping, animal foods and drugs, cosmetics, and more. They can be administered via inhalation, oral, buccal, or topical routes. Although widely marketed for the treatment of a variety of conditions, conclusive evidence regarding safety and efficacy of cannabis for therapeutic purposes is largely lacking. In a 2017 report, an expert committee of the National Academies of Sciences, Engineering, and Medicine (NASEM) conducted an in-depth, comprehensive review of the medical literature and characterized the strength of evidence regarding whether cannabis or cannabinoids are effective or ineffective for certain therapeutic conditions. They determined that there is "conclusive" or "substantial" evidence for efficacy for only 3 therapeutic uses: (1) antiemetic effects in chemotherapy-induced nausea and vomiting, (2) chronic pain in adults, and (3) multiple sclerosis-related spasticity as reported by patients 1 (the full report can be accessed at: nationalacademies.org/CannabisHealthEffects).
Of foremost importance in navigating the use of CBD products within the health system environment is understanding and complying with the current legal landscape. On the federal level, cannabis or marijuana has been controlled since 1970 under the Controlled Substance Act (CSA) as Schedule I due to high potential for abuse related to the THC component and no medically accepted therapeutic use, making it illegal for providers to prescribe or pharmacies to dispense. 2 The 2018 Farm Bill removed hemp, including cannabinoid, containing less than 0.3% THC on a dry weight basis from the CSA; therefore, it is no longer considered a controlled substance under federal law. However, this does not mitigate the authority of the Food and Drug Administration (FDA) to regulate cannabis products under the Food, Drug and Cosmetic (FD&C) Act. Although currently marketed CBD products span the range of categories that fall under the jurisdiction of the FDA, the scope and approach that the FDA will adopt in regulating these products are unclear. The FDA held a public hearing on May 31, 2019 to provide an opportunity for stakeholders to share their experiences with cannabis-related products and solicit input as to the current regulatory strategy. 3 Beyond consideration of federal regulations, state regulations must be considered and care taken to remain in compliance with the more restrictive law. For example, the State of Kansas recently excepted CBD from the definition of marijuana, descheduling CBD products from the Kansas Uniform Controlled Substances Act. 4 Although this currently applies only for products that contain zero THC, a bill is being considered that would allow CBD products to contain up to 5% THC as verified by a third-party, independent laboratory for patients with debilitating medical conditions. 5 If passed, this would exceed the allowable THC content (<0.3%) defined in the federal CSA allowing for deregulation of CBD products. This leaves health system providers in the gray zone of navigating provision of care to patients who readily have access to CBD products in the community, but the use of which may be restricted or denied within the health system setting due to concerns regarding compliance with federal law and maintaining their Drug Enforcement Administration (DEA) license. This confusion is amplified for health systems that have locations in multiple states or boarder states as regulations may differ and CBD products available to patients may not meet the legal requirement of the location where the patient is being admitted. This may require different policies or workflows for locations within the same health system creating confusion and frustration for patients and providers alike.
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Although is unlikely that CBD products would be added to formulary or otherwise procured and distributed by the health system, the health system may decide to allow patients to bring in and use their own CBD products under a Patient's Own Medication (POM) policy. In a recent survey within our health system, providers indicated that they were generally in favor of POM use of CBD products if deemed appropriate by their medical provider and that they should be treated in the same manner as herbals or dietary supplements. Joint Commission standards dictate that products brought into the institution by patients are to be identified prior to administration and visually inspected for their integrity. 6 However, there are unique challenges to identification of CBD products in that it is well documented that CBD product labeling may not accurately reflect the CBD and THC content. 7, 8 In addition, impurities such as pesticides and heavy metals have been identified. 9 This may unknowingly put a health system at risk of penalties due to violation of state and federal regulations. Furthermore, caution should be taken to ensure that POM use of CBD products is operationalized in a manner that can be construed as prescribing. For example, if a provider places a POM order within the electronic medical record so that the product shows up on the Medication Administration Record (MAR) and can be documented as given, that may technically be interpreted as prescribing and administering a product which may be a violation of the CSA depending on the THC content of the product. Beyond an institution's POM policy, a CBD-specific policy may be warranted to address these unique challenges as well as to outline appropriate storage and disposal requirements to ensure that products are handled in a secure manner as some CBD products come in forms (i.e., cookie, gummy bears) that may unknowingly lead to inadvertent exposure. Although it is likely that pharmacy will take a primary role in CBD-related policy development, it is imperative that other stakeholders such as regulatory and risk departments be involved to address the unique challenges regarding the use of non-FDA approved CBD products within the health system.
On June 25, 2018, the FDA approved CBD (Epidiolex) for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients at or above 2 years of age. 10 This marks the first FDA-approved drug with an active ingredient derived from cannabis. 11 Epidiolex contains trace amounts of THC (≤0.1% w/w; ≤0.01% in final product) 12 and is classified as Schedule V under the CSA. 10 Consequently, the FDA has taken a clear stance that CBD products do not meet the definition of a dietary supplement as under the FD&C Act a dietary supplement cannot contain the same active ingredient as an FDA-approved drug. 3 This approval provides an opportunity for better characterization of possible drug interactions, adverse effects, and monitoring requirements that may be associated with the use of CBD products. For example, Epidiolex labeling requires serum transaminase and total bilirubin levels be monitored prior to and throughout treatment for early identification and management of possible hepatocellular injury which is more common with concomitant use of valproate and clobazam. 10 However, it must be considered that non-FDA approved CBD products may likely contain unlabeled ingredients and impurities that may lead to unknown risks.
To effectively advise the health care team as to the appropriate use of CBD products for specific indications, use in special populations, management of drug interactions, and identification of possible adverse reactions, pharmacists will be called upon to apply their expertise in evaluating the rapidly growing body of medical literature beyond the use of traditional drug information resources. In addition, pharmacists should be prepared to counsel patients with evidencebased information to inform them of possible risks and counter the marketing messages that so prevalently tout CBD products as a cure-all without risk. 3, 9 
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